Target intelligence / Profile preview

Heterocyclic amines (HCA)

Target
HCA
Molecular classification
Environmental mutagen, Pro-carcinogen, Small molecule, Exogenous chemical
01

Overview

Heterocyclic amines (HCAs) are a class of potent mutagenic and carcinogenic chemical compounds formed when muscle meat, such as beef, pork, poultry, or fish, is cooked using high-temperature methods like pan-frying or grilling (National Cancer Institute, 2020). These substances are not therapeutic targets; rather, they are exogenous pro-carcinogens that require metabolic bioactivation within the host to exert toxic effects (IARC, 1993). The primary activation pathway involves N-oxidation by hepatic cytochrome P450 1A2 (CYP1A2), followed by esterification by phase II enzymes such as N-acetyltransferases (NAT) or sulfotransferases (SULT), resulting in highly reactive electrophilic intermediates (Turesky & Le Marchand, 2011; UniProt P05177). These reactive species form stable covalent adducts with DNA, particularly at guanine residues, which can lead to mutations in critical tumor suppressor genes and oncogenes like TP53 and KRAS (PubMed, PMC2847610). Epidemiological and experimental evidence strongly links high dietary HCA exposure to an increased risk of several human malignancies, including colorectal, prostate, and breast cancers (NIH, 2020). Consequently, HCAs are of significant concern in toxicology and public health, with research focusing on individual genetic susceptibility and dietary prevention strategies rather than pharmaceutical modulation (PubMed, 22107498).

Other names
Amino-azaarenesHeterocyclic aromatic aminesCooked meat mutagensAmino-polycyclic aromatic hydrocarbonsPhIPMeIQxIQ
02

Mechanism of action

Not applicable as a therapeutic target; these compounds act as pro-carcinogens that are metabolically activated to form DNA-reactive electrophiles.

03

Biological functions

DNA adduct formationGenotoxicityMutagenesisMetabolic bioactivation
04

Disease associations

Colorectal cancerBreast cancerProstate cancerPancreatic cancerGastric cancer
05

Safety considerations

CarcinogenicityGenotoxicityMutagenicityGenomic instability
06

Biomarkers

HCA-DNA adductsUrinary HCA metabolites2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx)PhIP-hemoglobin adducts

Beyond the preview

Go deeper on Heterocyclic amines (HCA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Heterocyclic amines (HCA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call